It is noted that TET2 mutations are consistently associated with a decrease in 5hmC, which has been suggested as a potential diagnostic and prognostic biomarker for hematopoietic malignancies, especially myeloid malignancies (4). The gene discussed is TET2; the disease is myeloid neoplasm.